News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioGentech Corp. (BGTH) Announces ClinDatrix, Inc. As CRO For Phase III Trials


10/19/2005 5:11:07 PM

BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergy medications, announced today that it has entered into an agreement with Irvine based ClinDatrix, Inc. for the implementation, management and analysis of clinical investigations of BioGentech's flagship product, Prehistin, for their upcoming Phase III trials.

Read at Prime Zone

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES